000661 长春高新
午间休市 09-09 11:30:00
资讯
新帖
简况
股市必读：长春高新（000661）9月4日董秘有最新回复
证券之星 · 09-07 01:03
股市必读：长春高新（000661）9月4日董秘有最新回复
长春高新子公司GenSci133注射液获批临床 拟用于治疗骨质疏松症
同花顺 · 09-04
长春高新子公司GenSci133注射液获批临床 拟用于治疗骨质疏松症
长春高新：子公司GenSci133注射液临床试验申请获批准
格隆汇 · 09-04
长春高新：子公司GenSci133注射液临床试验申请获批准
长春高新：截止2026年6月30日商誉相关期末余额为7556万元
证券之星 · 09-04
长春高新：截止2026年6月30日商誉相关期末余额为7556万元
国金证券：给予长春高新买入评级
证券之星 · 09-02
国金证券：给予长春高新买入评级
长春高新最新公告：子公司GenSci161注射液临床试验申请获受理
证券之星 · 08-31
长春高新最新公告：子公司GenSci161注射液临床试验申请获受理
股市必读：长春高新新发布《第十一届董事会第二十一次会议决议公告》
证券之星 · 08-31
股市必读：长春高新新发布《第十一届董事会第二十一次会议决议公告》
长春高新最新公告：全资子公司凯美斯制药获新发集团不超4亿元股权投资意向
证券之星 · 08-28
长春高新最新公告：全资子公司凯美斯制药获新发集团不超4亿元股权投资意向
长春高新：金赛佳®Ⅳ期临床试验聚焦高龄助孕群体
证券之星 · 08-24
长春高新：金赛佳®Ⅳ期临床试验聚焦高龄助孕群体
长春高新（000661）2026年中报简析：净利润同比下降51.64%
证券之星 · 08-22
长春高新（000661）2026年中报简析：净利润同比下降51.64%
8月21日长春高新跌5.69%，生物医药ETF国泰基金重仓该股
证券之星 · 08-21
8月21日长春高新跌5.69%，生物医药ETF国泰基金重仓该股
长春高新：8月20日接受机构调研，北京睿石泓远投资、东北证券等多家机构参与
证券之星 · 08-21
长春高新：8月20日接受机构调研，北京睿石泓远投资、东北证券等多家机构参与
图解长春高新中报：第二季度单季净利润同比下降60.88%
证券之星 · 08-21
图解长春高新中报：第二季度单季净利润同比下降60.88%
长春高新（000661）披露2026年限制性股票激励计划相关主体买卖公司股票情况的自查报告，8月20日股价上涨4.13%
证券之星 · 08-20
长春高新（000661）披露2026年限制性股票激励计划相关主体买卖公司股票情况的自查报告，8月20日股价上涨4.13%
长春高新：2026年上半年净利4.75亿元，同比下降51.64%
格隆汇 · 08-20
长春高新：2026年上半年净利4.75亿元，同比下降51.64%
股市必读：长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》
证券之星 · 08-14
股市必读：长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》
长春高新（000661）披露2026年限制性股票激励计划激励对象名单审核及公示情况说明，8月12日股价下跌0.71%
证券之星 · 08-12
长春高新（000661）披露2026年限制性股票激励计划激励对象名单审核及公示情况说明，8月12日股价下跌0.71%
长春高新（000661）披露子公司GenSci148注射液临床试验申请获批公告，8月10日股价上涨3.09%
证券之星 · 08-10
长春高新（000661）披露子公司GenSci148注射液临床试验申请获批公告，8月10日股价上涨3.09%
长春高新董秘李洪谕荣获第十二届金麒麟·金牌董秘荣誉
新浪财经 · 08-10
长春高新董秘李洪谕荣获第十二届金麒麟·金牌董秘荣誉
长春高新：公司以经营业绩为市值管理根本
证券之星 · 08-07
长春高新：公司以经营业绩为市值管理根本
加载更多
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是生长激素系列产品、促卵泡激素系列、金蓓欣（伏欣奇拜单抗）、美适亚（醋酸甲地孕酮）、安脱达（屋尘螨变应原制剂）等。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":74.72,"timestamp":1788926280000,"preClose":75.93,"halted":0,"volume":2496458,"delay":0,"changeRate":-0.0159,"floatShares":400000000,"shares":408000000,"eps":-0.8643,"marketStatus":"午间休市","change":-1.21,"latestTime":"09-09 11:30:00","open":75.22,"high":75.8,"low":74.58,"amount":187000000,"amplitude":0.0161,"askPrice":74.76,"askSize":7,"bidPrice":74.71,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-0.8643,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788930000000},"marketStatusCode":3,"adr":0,"adjPreClose":75.93,"symbolType":"stock","openAndCloseTimeList":[[1788917400000,1788924600000],[1788930000000,1788937200000]],"highLimit":83.52,"lowLimit":68.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.38,"roa":"--","roe":"2.14%","epsLYR":0.39,"committee":0.885542,"marketValue":30481000000,"turnoverRate":0.0062,"status":1,"floatMarketCap":29860000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2665290362","title":"股市必读：长春高新（000661）9月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665290362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665290362?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:03","pubTimestamp":1788714192,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，长春高新报收于73.74元，下跌0.46%，换手率1.0%，成交量3.99万手，成交额2.96亿元。董秘： 您好，根据公司2026年半年度报告，截止2026年6月30日商誉相关期末余额为7556万元，整体金额较少，同时公司根据会计准则等要求会持续关注商誉减值等情况，谢谢！当日关注点交易信息汇总：9月4日主力资金净流出588.87万元，占总成交额1.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0075","BK0028","BK0188","BK0057","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332229","title":"长春高新子公司GenSci133注射液获批临床 拟用于治疗骨质疏松症","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332229","media":"同花顺","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664332229?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:23","pubTimestamp":1788528180,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者田甜)长春高新9月4日晚发布公告称，公司控股子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的GenSci133注射液境内生产药 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260904/c679621278.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260904/c679621278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0028","000661","BK0046","BK0057","BK0188","BK0075","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387742","title":"长春高新：子公司GenSci133注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387742","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664387742?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:11","pubTimestamp":1788509503,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0075","BK0028","BK0046","BK0188","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387143","title":"长春高新：截止2026年6月30日商誉相关期末余额为7556万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664387143?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:06","pubTimestamp":1788509182,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：许多投资者担心公司商誉问题，请问公司是否考虑对商誉减值损失进行一次性计提，以出清市场风险？长春高新回复：您好，根据公司2026年半年度报告，截止2026年6月30日商誉相关期末余额为7556万元，整体金额较少，同时公司根据会计准则等要求会持续关注商誉减值等情况，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400026365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","BK0057","BK0188","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664895606","title":"国金证券：给予长春高新买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664895606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664895606?lang=zh_cn&edition=full","pubTime":"2026-09-02 12:14","pubTimestamp":1788322486,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司马居东近期对长春高新进行研究并发布了研究报告《业绩短期承压，创新转型加速》，给予长春高新买入评级。上半年金赛药业实现收入45.04亿元，较上年同期降低17.65%；实现归属于母公司所有者的净利润5.78亿元，较上年同期降低47.84%。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为102.77。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200019060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663951070","title":"长春高新最新公告：子公司GenSci161注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2663951070","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663951070?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:31","pubTimestamp":1788175864,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》，GenSci161注射液境内生产药品注册临床试验申请获受理。该药品为自主研发的治疗用生物制品1类药物，拟用于治疗结缔组织病相关间质性肺疾病，目前该领域临床需求缺口较大。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100031253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0075","BK0057","BK0188","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663304722","title":"股市必读：长春高新新发布《第十一届董事会第二十一次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663304722","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663304722?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:11","pubTimestamp":1788127874,"startTime":"0","endTime":"0","summary":"公司公告汇总第十一届董事会第二十一次会议决议公告长春高新于2026年8月28日召开第十一届董事会第二十一次会议，审议通过《关于全资子公司签署租赁合同暨关联交易的议案》和《关于全资子公司签署投资意向与合作框架协议暨关联交易的议案》，两项议案均获全体董事同意通过，独立董事专门会议已审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0075","BK0028","BK0046","BK0188","000661","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662622067","title":"长春高新最新公告：全资子公司凯美斯制药获新发集团不超4亿元股权投资意向","url":"https://stock-news.laohu8.com/highlight/detail?id=2662622067","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662622067?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:24","pubTimestamp":1787916245,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司全资子公司凯美斯制药与间接控股股东新发集团签署《投资意向与合作框架协议》，新发集团计划通过资本运作等方式对凯美斯制药进行总额不超过4亿元的股权投资，分三个阶段推进，首期投资不超过3500万元，用于启动生产。本次交易构成关联交易，已获董事会审议通过，无需提交股东会审议。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800045261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0075","BK1574","01477","BK0057","BK0046","BK0239","BK1191","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241008","title":"长春高新：金赛佳®Ⅳ期临床试验聚焦高龄助孕群体","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241008","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661241008?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:57","pubTimestamp":1787533024,"startTime":"0","endTime":"0","summary":"长春高新回复：您好，公司金赛佳 于2025 年 9 月已正式获得国家药品监督管理局核准签发的《药品注册证书》，批准的适应症为：与促性腺激素释放激素拮抗剂联合使用，用于控制性卵巢刺激，以诱导多个卵泡发育。本研究聚焦于高龄助孕群体，开展金赛佳 绒促卵泡激素α N02 注射液的Ⅳ期临床试验，旨在补充该药物用于高龄患者的高质量临床数据，为高龄助孕人群用药提供更为充分、可靠的循证医学证据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400003009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0239","BK0188","BK0028","BK0046","BK0057"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661221834","title":"长春高新（000661）2026年中报简析：净利润同比下降51.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221834","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661221834?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:08","pubTimestamp":1787350108,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期长春高新发布2026年中报。截至本报告期末，公司营业总收入55.43亿元，同比下降16.06%，归母净利润4.75亿元，同比下降51.64%。按单季度数据看，第二季度营业总收入29.55亿元，同比下降18.03%，第二季度归母净利润2.0亿元，同比下降60.88%。持有长春高新最多的基金为生物医药ETF国泰，目前规模为37.03亿元，最新净值1.0716，较上一交易日下跌3.52%，近一年上涨0.33%。本文数据来源于长春高新2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200004925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661426547","title":"8月21日长春高新跌5.69%，生物医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661426547","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661426547?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:43","pubTimestamp":1787301791,"startTime":"0","endTime":"0","summary":"证券之星消息，8月21日长春高新跌5.69%，收盘报79.5元，换手率3.15%，成交量12.59万手，成交额10.18亿元。重仓长春高新的前十大公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为国泰基金的生物医药ETF国泰。生物医药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["512290","BK0046","000661","BK0075","BK0239","BK0057","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661253099","title":"长春高新：8月20日接受机构调研，北京睿石泓远投资、东北证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2661253099","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661253099?lang=zh_cn&edition=full","pubTime":"2026-08-21 08:43","pubTimestamp":1787273029,"startTime":"0","endTime":"0","summary":"2026 年上半年，公司实现营业收入 55.43 亿元，较上年同期降低 16.06%；实现归属于上市公司股东净利润 4.75 亿元，较上年同期降低 51.64%。高新地产实现收入 13.91 亿元，较上年同期增长 202.56%；实现归属于母公司所有者的净利润 0.01 亿元。2026 年上半年，管理费用 5.72 亿元，同比降低 21.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100008619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000686","BK0188","BK0075","BK0057","BK0239","000661","BK0028","BK0276","BK0183","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661239314","title":"图解长春高新中报：第二季度单季净利润同比下降60.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661239314","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661239314?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:21","pubTimestamp":1787246471,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新2026年中报显示，上半年度公司主营收入55.43亿元，同比下降16.06%；归母净利润4.75亿元，同比下降51.64%；扣非净利润4.96亿元，同比下降52.02%；其中2026年第二季度，公司单季度主营收入29.55亿元，同比下降18.03%；单季度归母净利润2.0亿元，同比下降60.88%；单季度扣非净利润2.13亿元，同比下降60.58%；负债率17.76%，投资收益-3822.76万元，财务费用2223.3万元，毛利率78.84%。财报数据概要请见下图:本文数据来源于长春高新2026年中报，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400261","title":"长春高新（000661）披露2026年限制性股票激励计划相关主体买卖公司股票情况的自查报告，8月20日股价上涨4.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400261?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:31","pubTimestamp":1787218308,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，长春高新报收于84.3元，较前一交易日上涨4.13%，最新总市值为343.89亿元。该股当日开盘83.4元，最高85.16元，最低82.41元，成交额达11.43亿元，换手率为3.4%。公告显示，公司对2026年限制性股票激励计划内幕信息知情人及首次授予激励对象在自查期间买卖公司股票的情况进行了自查。公司未发现内幕信息知情人利用相关内幕信息买卖股票的行为，符合《上市公司股权激励管理办法》相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0075","BK0239","BK0057","000661","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407532","title":"长春高新：2026年上半年净利4.75亿元，同比下降51.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407532","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660407532?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:58","pubTimestamp":1787216300,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["000661","BK0188","BK0075","BK0028","BK0046","BK0057","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659916962","title":"股市必读：长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916962","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659916962?lang=zh_cn&edition=full","pubTime":"2026-08-14 00:57","pubTimestamp":1786640229,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，长春高新报收于85.45元，下跌0.85%，换手率2.52%，成交量10.07万手，成交额8.7亿元。当日关注点交易信息汇总：8月13日主力资金净流出1750.86万元，占总成交额2.01%。公司公告汇总：2026年限制性股票激励计划激励对象名单公示期结束，未收到异议；董事会薪酬与考核委员会确认激励对象主体资格合法有效，且不包括董事、高管、总部及控股子公司人员，亦不含持股5%以上股东及其亲属。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0188","BK0075","000661","BK0239","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903944","title":"长春高新（000661）披露2026年限制性股票激励计划激励对象名单审核及公示情况说明，8月12日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903944?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:05","pubTimestamp":1786543520,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，长春高新报收于86.18元，较前一交易日下跌0.71%，最新总市值为351.56亿元。该股当日开盘86.78元，最高88.58元，最低86.0元，成交额达9.7亿元，换手率为2.79%。近日，长春高新技术产业（集团）股份有限公司披露《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》。激励对象主体资格合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200039938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0239","BK0075","BK0057","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658932501","title":"长春高新（000661）披露子公司GenSci148注射液临床试验申请获批公告，8月10日股价上涨3.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658932501","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658932501?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:14","pubTimestamp":1786371256,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，长春高新报收于83.0元，较前一交易日上涨3.09%，最新总市值为338.59亿元。该股当日开盘80.9元，最高83.73元，最低80.5元，成交额达11.06亿元，换手率为3.35%。近日，长春高新技术产业（集团）股份有限公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，GenSci148注射液境内生产药品注册临床试验申请获得批准。临床试验后续进程及结果存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000033912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","000661","BK0188","BK0239","BK0057","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658985916","title":"长春高新董秘李洪谕荣获第十二届金麒麟·金牌董秘荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2658985916","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658985916?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:27","pubTimestamp":1786346820,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级专题：专题：第十二届金麒麟·金牌董秘及优秀证代荣誉榜单揭晓！8月10日，新浪财经第十二届金麒麟金牌董秘榜单正式揭晓。长春高新董事会秘书李洪谕凭借扎实的合规治理能力、成熟的投资者关系运营、长期稳健的资本价值传递表现，荣耀加冕第十二届金麒麟金牌董秘。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-08-10/doc-inimvhfr4982251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0075","BK0028","BK0239","BK0046","000661","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657194566","title":"长春高新：公司以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2657194566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657194566?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:18","pubTimestamp":1786094289,"startTime":"0","endTime":"0","summary":"公司管理层高度重视市值管理工作，但二级市场股价受宏观环境、行业周期、市场情绪等多重因素影响。公司未来若有达到信息披露要求的市值管理相关举措安排，将严格履行决策程序并及时对外披露，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","BK0188","BK0239","BK0057","000661","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788926313706,"stockEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":-0.0569},{"period":"3month","weight":0.1477},{"period":"6month","weight":-0.1563},{"period":"1year","weight":-0.4032},{"period":"ytd","weight":-0.1779}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"130136人(较上一季度减少5.79%)","perCapita":"3070股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是生长激素系列产品、促卵泡激素系列、金蓓欣（伏欣奇拜单抗）、美适亚（醋酸甲地孕酮）、安脱达（屋尘螨变应原制剂）等。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}